Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/8/2017
SIETES contiene 91969 citas

 
 
 1 a 20 de 31 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2.Tiene citas relacionadas Cita con resumen
Keaney Jr JF. Balancing the risks and benefits of dual platelet inhibition. N Engl J Med 2015;372:1854-6. [Ref.ID 99087]
3.Tiene citas relacionadas Cita con resumen
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800. [Ref.ID 99086]
4.Tiene citas relacionadas Cita con resumen
Thornton JG. HRT and cardiovascular events. Press release was misleading. BMJ 2012;345:27. [Ref.ID 94212]
5.Tiene citas relacionadas Cita con resumen
Schierbeck LL, Kober L, Jensen J-EB. HRT and cardiovascular events. Author's reply. BMJ 2012;345:27. [Ref.ID 94211]
6.Tiene citas relacionadas Cita con resumen
McPherson K. HRT and cardiovascular events. Age hypothesis does not stand. BMJ 2012;345:27. [Ref.ID 94210]
7.Tiene citas relacionadas Cita con resumen
Schroll J, Lundh A. HRT and cardiovascular events. Was composite outcome specified in original protocol?. BMJ 2012;345:26-7. [Ref.ID 94209]
8.Tiene citas relacionadas Cita con resumen
Rossouw JE, Manson JE, Kaunitz AM, Stefanick ML. HRT and cardiovascular events. Safety couldn't be investigated. BMJ 2012;345:26. [Ref.ID 94208]
9.Tiene citas relacionadas Cita con resumen
Marjoribanks J, Farquhar C, Roberts H, Lethaby A. HRT and cardiovascular events. Trial does not change results of Cochrane review. BMJ 2012;345:26. [Ref.ID 94207]
10.Enlace a cita original Cita con resumen
Fraga Fuentes MD, Tenías Burillo JM, Ruiz Martín de la Torre R, López Sánchez P, Jerez Fernández E, Valenzuela Gámez JC. Dar sentido a las evidencias: aspectos claves a valorar en los ensayos clínicos sobre medicamentos. Boletín Farmacoterapéutico de Castilla-La Mancha 2012;23:1-8. [Ref.ID 92717]
11. Cita con resumen
Juurlink DN. Proton pump inhibitors and clopidogrel: Putting the interaction in perspective. Circulation 2009;120:2310-2. [Ref.ID 87817]
13.Tiene citas relacionadas Cita con resumen
Mega JL, Braunwald E, Gibson CM. Underestimation of the effect of bleeding in clinical trials. Authors' reply. Lancet 2009;374:1145-6. [Ref.ID 86873]
14.Tiene citas relacionadas Cita con resumen
Stewart RA. Underestimation of the effect of bleeding in clinical trials. Lancet 2009;374:1145. [Ref.ID 86872]
15. Cita con resumen
Pocock SJ, Ware JH. Translating statistical findings into plain English. Lancet 2009;373:1926-8. [Ref.ID 85993]
18.Tiene citas relacionadas Cita con resumen
Boutitie F, Gueyffier F, Achard J-M, Temmar M, Fournier A. The JIKEI trial. Lancet 2007;370:1825-6. [Ref.ID 81658]
19.Tiene citas relacionadas Cita con resumen
Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N, for the Jikei Heart Study group. Valsartan in Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9. [Ref.ID 79927]
20.Tiene citas relacionadas Cita con resumen
Staessen JA, Richart T. Sum and substance in the Jikei Heart Study. Lancet 2007;369:1407-8. [Ref.ID 79917]
Seleccionar todas
 
 1 a 20 de 31 siguiente >>